DEVELOPMENT AND EVALUATION OF MOUTH DISSOLVING TABLETS OF OMEPRAZOLE FOR ENHANCED BIOAVAILABILITY

The purpose of this research was to examine the development of a mouth-dissolving tablet formulation of omeprazole to enhance its rapid absorption through the buccal mucosa, which would facilitate the onset of therapeutic effects more quickly. Formulation was difficult for omeprazole because of its low solubility and permeability, which places it in the IV class of drugs according to the Biopharmaceutics Classification System. For the preparation of the tablets, the wet granulation method was utilized, which ensured that the drug-excipient ratios were consistent throughout. All of the formulations were able to satisfy the pharmacopeial standards for weight consistency, friability, thickness, and drug content. The results of the in-vitro tests showed that the disintegration and dispersion properties were outstanding, which indicated that the bioavailability and drug release kinetics were more favorable. Over four weeks at a temperature of 50℃, accelerated stability testing indicated consistent drug content, hardness, and in-vitro dispersion time. This indicates that the formulation has been stable for more than a year. Because the newly created formulation shows superior medicine release patterns, favorable disintegration time, hardness, and friability, it is a prospective candidate for the oral delivery of omeprazole that has enhanced therapeutic efficacy.